NCT07374445

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

The Timing for Liraglutide in Patients Remaining Obese at 6 Months After Metabolic Surgery: an Observational Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are: \[primary hypothesis 1\] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery. \[primary hypothesis 2\] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Conditions

• Obesity
• Weight Loss
• Bariatric Surgery

Interventions

Type	Name	Description
DRUG	Liraglutide injection	Patients received a 24-week regimen of once-daily liraglutide, initiated at 0.6 mg/day and titrated weekly by 0.6 mg to a maximum tolerated dose of up to 3.0 mg/day.
BEHAVIORAL	Diet and exercise guidelines	Participants followed a science-based diet and exercise program intervention

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2026-01-28
• Last updated: 2026-01-28

Locations

1 site across 1 country: China